Citations

Clear

1446 citation(s) found for "Howard, F".

Filial Piety in Palliative Care: Faithfully Following Family Feelings. Or Is It?
Howard, B, Shannon, Robert P.

Mayo Clinic

Journal of Palliative Medicine | March 28, 2013 | Volume: 16 | Issue: 5 | Pages: 584-585

10.1089/jpm.2012.0372 | PMID 23537195 Get It

Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity
Jahanshad, Neda , Rajagopalan, Priya , Hua, Xue , Hibar, Derrek P., Nir, Talia M. , Toga, Arthur W. , Jack, Clifford R., Saykin, Andrew J. , Weiner, Michael W. , Medland, Sarah E. , Montgomery, Grant W. , Hansell, Narelle K. , McMahon, Katie L. , Zubicaray, Greig I. de , Martin, Nicholas G. , Wright, Margaret J. , Thompson, Paul M. , Initiative, the Alzheimer’s Disease Neuroimaging, Aisen, Paul, Petersen, Ronald, Jagust, William J. , Trojanowski, John Q. , Toga, Arthur W., Green, Robert C., Liu, Enchi , Green, Robert C., Montine, Tom, Gamst, Anthony, Thomas, Ronald G. , Donohue, Michael, Walter, Sarah , Gessert, Devon, Sather, Tamie, Harvey, Danielle, Donohue, Michael, Kornak, John , Jack, Clifford R., Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Trojanowki, John Q., Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Khachaturian, Zaven S., Frank, R.T., Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Chowdhury, Munir , Bell, Karen L. , Carroll, Maria , Leon, Sue, Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varon, Daniel, Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, Robert E. , Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard , Bergman, Howard , Hosein, Chris, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Feldman, Howard J., Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy E., Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan, Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T.-Y., Bartha, Robert , Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J., Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Lee, Ting‐Yim , Jack, Clifford R., Green, Robert C. , Initiative, the Alzheimer’s Disease Neuroimaging, Jack, Clifford R. , Toga, Arthur W., Beckett, Laurel , Green, Robert C., Morris, John C. , Green, Robert C., Donohue, Michael, Sather, Tamie, Donohue, Michael, Jack, Clifford R., Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Toga, Arthur W., Foroud, Tatiana , Potkin, Steven G. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Villanueva-Meyer, Javier E. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Grossman, Hillel, Shah, Raj C. , Duara, Ranjan , Varón, Daniel , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Weiner, Myron , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather M. , Black, Sandra E. , Stefanovic, Bojana , Kertesz, Andrew, Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Johnson, Keith A. , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Kertesz, Andrew, de Zubicaray, Greig I , Hansell, Narelle K , Saykin, Andrew J , Preda, Adrian , Martin, Nicholas G , Toga, Arthur W , Wright, Margaret J , Thompson, Paul M , Medland, Sarah E , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Proceedings of the National Academy of Sciences | March 5, 2013 | Volume: 110 | Issue: 12 | Pages: 4768-4773

10.1073/pnas.1216206110 | PMID 23471985 Get It

Aberrant connectivity is implicated in many neurological and psychiatric disorders, including Alzheimer’s disease and schizophrenia. However, other than a few disease-associated candidate genes, we know little about the degree to which genetics play a role in the brain networks; we know even less about specific genes that influence brain connections. Twin and family-based studies can generate estimates of overall genetic influences on a trait, but genome-wide association scans (GWASs) can screen the genome for specific variants influencing the brain or risk for disease. To identify the heritability of various brain connections, we scanned healthy young adult twins with high-field, high-angular resolution diffusion MRI. We adapted GWASs to screen the brain’s connectivity pattern, allowing us to discover genetic variants that affect the human brain’s wiring. The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample. rs2618516 was shown to affect brain structure in an elderly population with varying degrees of dementia. Older people who carried the connectivity variant had significantly milder clinical dementia scores and lower risk of Alzheimer’s disease. As a posthoc analysis, we conducted GWASs on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism ( MACROD2 ), development ( NEDD4 ), and mental retardation ( UBE2A ) significantly associated with connectivity. Connectome-wide, genome-wide screening offers substantial promise to discover genes affecting brain connectivity and risk for brain diseases.
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, María C. , Brashear, H. Robert, Logovinsky, Veronika, Ryan, J. Michael, Feldman, Howard , Siemers, Eric , Abushakra, Susan, Hartley, Dean M. , Petersen, Ronald C. , Khachaturian, Ara S. , Sperling, Reisa Anne , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | February 11, 2013 | Volume: 9 | Issue: 2 | Pages: 123

10.1016/j.jalz.2012.12.004 | PMID 23411394 Get It

Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
Valvular Heart Disease in Patients with Osteogenesis Imperfecta
Najib, Mohammad Q. , Schaff, Hartzell V. , Ganji, Jhansi L., Lee, Howard R., Click, Roger L., Chaliki, Hari P. , Miller, D. Craig , Schaff, Hartzell

Mayo Clinic

Journal of Cardiac Surgery | January 24, 2013 | Volume: 28 | Issue: 2 | Pages: 139-143

10.1111/jocs.12064 | PMID 23347109 Get It

Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study
Miller, Virginia M. , Petterson, Tanya M. , Jeavons, Elysia N, Lnu, Abhinita S., Rider, David N., Heit, John A. , Cunningham, Julie M. , Huggins, Gordon S. , Hodis, Howard N., Budoff, Matthew J. , Hopkins, Paul N. , Løbo, Rogerio A. , Taylor, Hugh S. , Harman, S. Mitchell , Santoro, Nanette F. , Manson, JoAnn E. , Naftolin, Frederick , Andrade, Mariza de , Budoff, Matthew

Mayo Clinic

Physiological Genomics | November 28, 2012 | Volume: 45 | Issue: 2 | Pages: 79-88

10.1152/physiolgenomics.00114.2012 | PMID 23188791 Get It

Menopausal hormone treatment (MHT) may limit progression of cardiovascular disease (CVD) but poses a thrombosis risk. To test targeted candidate gene variation for association with subclinical CVD defined by carotid artery intima-media thickness (CIMT) and coronary artery calcification (CAC), 610 women participating in the Kronos Early Estrogen Prevention Study (KEEPS), a clinical trial of MHT to prevent progression of CVD, were genotyped for 13,229 single nucleotide polymorphisms (SNPs) within 764 genes from anticoagulant, procoagulant, fibrinolytic, or innate immunity pathways. According to linear regression, proportion of European ancestry correlated negatively, but age at enrollment and pulse pressure correlated positively with CIMT. Adjusting for these variables, two SNPs, one on chromosome 2 for MAP4K4 gene (rs2236935, β = 0.037, P value = 2.36 × 10−06) and one on chromosome 5 for IL5 gene (rs739318, β = 0.051, P value = 5.02 × 10−05), associated positively with CIMT; two SNPs on chromosome 17 for CCL5 (rs4796119, β = −0.043, P value = 3.59 × 10−05; rs2291299, β = −0.032, P value = 5.59 × 10−05) correlated negatively with CIMT; only rs2236935 remained significant after correcting for multiple testing. Using logistic regression, when we adjusted for waist circumference, two SNPs (rs11465886, IRAK2, chromosome 3, OR = 3.91, P value = 1.10 × 10−04; and rs17751769, SERPINA1, chromosome 14, OR = 1.96, P value = 2.42 × 10−04) associated positively with a CAC score of >0 Agatston unit; one SNP (rs630014, ABO, OR = 0.51, P value = 2.51 × 10−04) associated negatively; none remained significant after correcting for multiple testing. Whether these SNPs associate with CIMT and CAC in women randomized to MHT remains to be determined.
Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, Chen , Steplowski, Emily, Brotzman, Michelle, Xu, Mousheng, Mudgal, Poorva, Ámundadóttir, Laufey T. , Arslan, Alan A. , Bueno‐de‐Mesquita, H. Bas, Gross, Myron D., Helzlsouer, Kathy J., Jacobs, Eric J. , Petersen, Gloria M. , Zheng, Wei , Buring, Julie E. , Canzian, Federico , Cao, Guangwen , Duell, Eric J. , Elena, Joanne W. , Gaziano, J. Michael , Giovannucci, Edward L. , Hallmans, Göran, Hutchinson, Amy , Hunter, David J., Jenab, Mazda , Jiang, Guoliang , LaCroix, Andrea Z. , Li, Zhaoshen , Mendelsohn, Julie B., Panico, Salvatore , Patel, Alpa V. , Qian, Zhi Rong , Ríboli, Elio , Sesso, Howard D. , Shen, Hongbing , Shu, Xiao‐Ou , Tjønneland, Anne , Tobias, Geoffrey S. , Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala , Wactawski‐Wende, Jean , Wang, Chengfeng , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Hartge, Patricia, Fuchs, Charles S. , Lin, Dongxin , Wolpin, Brian M. , Kraft, Peter , Stolzenberg‐Solomon, Rachael Z. , Kooperberg, Charles , Albanes, Demetrius , Boutron‐Ruault, Marie‐Christine , Khaw, Kay‐Tee , Chanock, Stephen Jacob , Amundadottir, Laufey , Duell, Eric J , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Shu, Xiao-Ou , Visvanathan, Kala , Jenab, Mazda , Zheng, Wei , Cao, Guangwen , Riboli, Elio , Zeleniuch-Jacquotte, Anne , Shen, Hongbing

Mayo Clinic

Gut | November 24, 2012 | Volume: 63 | Issue: 1 | Pages: 152-160

10.1136/gutjnl-2012-303477 | PMID 23180869 Get It

Background and objective Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. Methods We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional hazards regression was used in an additive genetic model with adjustment for age, sex, clinical stage and the top four principal components of population stratification. The first stage included 642 cases of European ancestry (PanScan), from which the top SNPs (p≤10 −5 ) were advanced to a joint analysis with 363 additional patients from China (ChinaPC). Results In the first stage of cases of European descent, the top-ranked loci were at chromosomes 11p15.4, 18p11.21 and 1p36.13, tagged by rs12362504 (p=1.63×10 −7 ), rs981621 (p=1.65×10 −7 ) and rs16861827 (p=3.75×10 −7 ), respectively. 131 SNPs with p≤10 −5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; p=1.72×10 −7 ) on chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The HR (95% CI) for death was 0.74 (0.66 to 0.84) in PanScan I, 0.79 (0.65 to 0.97) in ChinaPC and 0.76 (0.68 to 0.84) in the joint analysis. Conclusions Germline genetic variation in the SBF2 locus was associated with overall survival in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association should be investigated in additional large patient cohorts.
Stroke After Carotid Stenting and Endarterectomy in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Hill, Michael D. , Brooks, William H. , Mackey, Ariane , Clark, Wayne M. , Morrish, William, Mohr, J.P. , Rhodes, J. , Popma, Jeffrey J. , Lal, Brajesh K. , Longbottom, Mary, Voeks, Jenifer H. , Howard, George , Brott, Thomas G. , Investigators, for the CREST, Meschia, James F. , Investigators, for the CREST, Hill, Michael D , Howard, George

Mayo Clinic

Circulation | November 18, 2012 | Volume: 126 | Issue: 25 | Pages: 3054-3061

10.1161/circulationaha.112.120030 | PMID 23159552 Get It

Background— Stroke occurs more commonly after carotid artery stenting than after carotid endarterectomy. Details regarding stroke type, severity, and characteristics have not been reported previously. We describe the strokes that have occurred in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Methods and Results— CREST is a randomized, open-allocation, controlled trial with blinded end-point adjudication. Stroke was a component of the primary composite outcome. Patients who received their assigned treatment within 30 days of randomization were included. Stroke was adjudicated by a panel of board-certified vascular neurologists with secondary central review of clinically obtained brain images. Stroke type, laterality, timing, and outcome were reported. A periprocedural stroke occurred among 81 of the 2502 patients randomized and among 69 of the 2272 in the present analysis. Strokes were predominantly minor (81%, n=56), ischemic (90%, n=62), in the anterior circulation (94%, n=65), and ipsilateral to the treated artery (88%, n=61). There were 7 hemorrhages, which occurred 3 to 21 days after the procedure, and 5 were fatal. Major stroke occurred in 13 (0.6%) of the 2272 patients. The estimated 4-year mortality after stroke was 21.1% compared with 11.6% for those without stroke. The adjusted risk of death at 4 years was higher after periprocedural stroke (hazard ratio, 2.78; 95% confidence interval, 1.63–4.76). Conclusions— Stroke, particularly severe stroke, was uncommon after carotid intervention in CREST, but stroke was associated with significant morbidity and was independently associated with a nearly 3-fold increased future mortality. The delayed timing of major and hemorrhagic stroke after revascularization suggests that these strokes may be preventable. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00004732.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Boxer, Adam L. , Huey, Edward D. , Hu, William T. , Rosen, Howard J. , Kramer, Joel H. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J., Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Jackson, George R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Abushakra, Susan, Lewcock, Joseph W. , Farese, Robert V. , Kenet, Robert O. , LaFerla, Frank M. , Perrin, Steve, Whitaker, Steve, Grossman, Murray, Gold, Michael , Kao, Aimee W. , Knopman, David S. , Honig, Lawrence S. , Mesulam, Marsel M. , Boeve, Bradley F. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H , Hu, William T.

Mayo Clinic

Alzheimer's & Dementia | October 10, 2012 | Volume: 9 | Issue: 2 | Pages: 189-198

10.1016/j.jalz.2012.03.003 | PMID 23062850 Get It

Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Boxer, Adam L. , Huey, Edward D. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J. , Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Farese, Robert V. , Gold, Michael , Kao, Aimee W. , Knopman, David S. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | October 5, 2012 | Volume: 9 | Issue: 2 | Pages: 176-188

10.1016/j.jalz.2012.03.002 | PMID 23043900 Get It

Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled “FTD, the Next Therapeutic Frontier,” which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.